KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Pacific Biosciences Of California (PACB) Invested Capital (2016 - 2026)

Pacific Biosciences Of California has reported Invested Capital over the past 16 years, most recently at $5.3 million for Q4 2025.

  • For Q4 2025, Invested Capital fell 98.94% year-over-year to $5.3 million; the TTM value through Dec 2025 reached $5.3 million, down 98.94%, while the annual FY2025 figure was $5.3 million, 98.94% down from the prior year.
  • Invested Capital for Q4 2025 was $5.3 million at Pacific Biosciences Of California, down from $36.1 million in the prior quarter.
  • Over five years, Invested Capital peaked at $1.1 billion in Q2 2023 and troughed at $5.3 million in Q4 2025.
  • A 5-year average of $523.4 million and a median of $626.6 million in 2022 define the central range for Invested Capital.
  • Biggest five-year swings in Invested Capital: surged 523.9% in 2021 and later tumbled 98.94% in 2025.
  • Year by year, Invested Capital stood at $792.6 million in 2021, then decreased by 7.27% to $735.0 million in 2022, then dropped by 4.58% to $701.3 million in 2023, then decreased by 27.76% to $506.6 million in 2024, then tumbled by 98.94% to $5.3 million in 2025.
  • Business Quant data shows Invested Capital for PACB at $5.3 million in Q4 2025, $36.1 million in Q3 2025, and $61.5 million in Q2 2025.